Jacobs & Co’s Moderna MRNA Stock Holding History

Jacobs & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-745	Closed	-$286K	–	125
2021 Q3	$286K	Buy	+745	New	+$275K	0.03%	106

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jacobs & Co's MRNA Position: Q4 2021 in Review

Jacobs & Co sold out of Moderna (MRNA) in Q4 2021, closing a stake of 745 shares — an estimated $286K sold.

Jacobs & Co first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $286K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Jacobs & Co reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Jacobs & Co sold 745 Moderna shares in Q4 2021, an estimated $286K.
Jacobs & Co first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Jacobs & Co's Moderna position peaked at $286K in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Jacobs & Co's 13F filing for Q4 2021, filed 21 Jan 2022.